Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lunai Bioworks Inc.RENB · Entity 7981 | Director | November 04, 2024 | November 06, 2024 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | June 04, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lunai Bioworks Inc.
Report date November 04, 2024 · Filed November 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase shares of common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2034-11-04 | Direct | 120,968 |
Reported balance
After 2024-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-04 · Grant · Acquired 120,968 · Balance 120,968 |
ZEVRA THERAPEUTICS, INC.
Report date June 04, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2036-06-03 | Direct | 30,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.
F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 18, 2026 20:15 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001434647-26-000052 · wk-form4_1781813748.xml · derivative · entry 1 Calder Douglas W · CIK 0001510445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 29, 2025 Filed May 31, 2025 01:39 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001437749-25-019048 · rdgdoc.xml · derivative · entry 1 Calder Douglas W · CIK 0001510445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-05-28 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| November 04, 2024 Filed Nov 6, 2024 21:54 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 120,968 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001731122-24-001729 · ownership.xml · derivative · entry 1 Calder Douglas W · CIK 0001510445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,968 Underlying: Common stock · 120,968 shares Expires 2034-11-04 Read SEC document |
| May 13, 2024 Filed May 16, 2024 01:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 39,200 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001437749-24-017181 · rdgdoc.xml · derivative · entry 1 Calder Douglas W · CIK 0001510445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,200 Underlying: Common Stock · 39,200 shares Expires 2034-05-12 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 13, 2024. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) one day prior to the date of the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 03, 2023 Filed May 12, 2023 00:02 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 58,800 | $0.00 Strike: $4.97 | $0.00 |
DisclosureSEC source: 0001437749-23-014014 · rdgdoc.xml · derivative · entry 1 Calder Douglas W · CIK 0001510445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,800 Underlying: Common Stock · 58,800 shares Expires 2033-05-02 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 3, 2023. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: 33.33% of the total shares subject to the option vest in equal annual installments beginning one day prior to the date of the first annual meeting of the Issuer's stockholders following the day of grant and continuing for the next two annual meeting of the Issuer's stockholders, such that the option will be fully vested one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.